| Literature DB >> 33150432 |
Xingjian Hu1,2, Yin Wang1, Junwei Liu1, Xuefeng Qiu1, Xiaobin Liu1, Xionggang Jiang1, Xiaofan Huang1, Xianqing Feng1, Yulin Zhang3, Songlin Zhang4, Haiyun Qian5, Wei Liu6, Jun Zhang7, Jiashou Dong8, Jiajun Chen9, Jiahong Xia1, Nianguo Dong1,2, Long Wu1.
Abstract
OBJECTIVES: Our goal was to compare the short-term outcomes of Stanford type A aortic dissection (TAAD), during the coronavirus disease 2019 (COVID-19) pandemic with those during normal times and summarize our perioperative management experience of patients with TAAD in the context of COVID-19.Entities:
Keywords: Acute aortic dissection; Coronavirus disease 2019; Emergency operation; Propensity score match; Stanford type A aortic dissection
Year: 2020 PMID: 33150432 PMCID: PMC7665539 DOI: 10.1093/icvts/ivaa209
Source DB: PubMed Journal: Interact Cardiovasc Thorac Surg ISSN: 1569-9285
Figure 1:Flow chart of the perioperative management of patients who may have TAAD during the COVID-19 pandemic. *Including tests for influenza type A and B, respiratory syncytial virus, Coxsackie group B virus, adenovirus, Mycoplasma pneumoniae and Chlamydia pneumoniae. #For patients with rapidly deteriorating conditions who cannot wait for the qRT-PCR test results or during the early phase when the qRT-PCR kit is in short supply. §Including complete blood count, c-reactive protein test and others. ¶Including myocardial enzymology, brain natriuretic peptide analysis and others. †qRT-PCR of pharyngeal swab samples. COVID-19: coronavirus disease 2019; CT: computed tomography; CTA: computed tomography angiography; ICU: intensive care unit; OR: operating room; PPE: personal protective equipment; qRT-PCR: quantitative real-time polymerase chain reaction; RT-PCR: real-time polymerase chain reaction; SARS-Cov-2: severe acute respiratory syndrome coronavirus 2; TAAD: type A aortic dissection; UCG: ultrasonic cardiography.
Preoperative characteristics
| Variables | Total ( | Non-matched cohort | Propensity matched cohort | ||||
|---|---|---|---|---|---|---|---|
| COVID-19 group January 2020–March 2020 ( | Control group January 2019–March 2019 ( |
| COVID-19 group January 2020–March 2020 ( | Control group January 2019–March 2019 ( |
| ||
| General | |||||||
| Age (years), mean ± SD | 52.3 ± 13.2 | 51.1 ± 13.1 | 52.7 ± 14.8 | 0.614 | 50.3 ± 12.6 | 51.7 ± 12.5 | 0.644 |
| Male gender | 85 (72.0) | 20 (74.1) | 65 (71.4) | 0.788 | 20 (76.9) | 37 (71.2) | 0.588 |
| BMI(kg/m2), mean ± SD | 24.1 ± 4.1 | 24.4 ± 3.7 | 24.0 ± 4.3 | 0.397 | 24.4 ± 3.8 | 24.2 ± 3.7 | 0.824 |
| Smoking | 66 (55.9) | 15 (55.6) | 51 (56.0) | 0.964 | 14 (53.8) | 29 (55.8) | 0.872 |
| Risk factors | |||||||
| Hypertension | 92 (78.0) | 18 (66.7) | 74 (81.3) | 0.107 | 17 (65.4) | 39 (75) | 0.374 |
| Diabetes | 28 (30.8) | 9 (33.3) | 19 (20.9) | 0.219 | 8 (30.8) | 13 (17.3) | 0.588 |
| COPD | 29 (24.6) | 6 (22.2) | 23 (25.3) | 0.746 | 5 (19.2) | 11 (21.2) | 0.811 |
| Coronary disease | 12 (10.2) | 2 (7.4) | 10 (11.0) | 0.589 | 2 (7.7) | 6 (11.5) | 0.653 |
| Cerebrovascular disease | 14 (11.9) | 1 (3.7) | 13 (14.3) | 0.135 | 1 (3.8) | 8 (15.4) | 0.174 |
| Hypertension | 92 (78.0) | 18 (66.7) | 74 (81.3) | 0.107 | 17 (65.4) | 39 (75) | 0.374 |
| Clinical presentation | |||||||
| Cardiogenic shock | 4 (3.4) | 0 (0) | 4 (4.4) | 0.268 | 0 (0) | 2 (3.8) | 0.302 |
| Stroke | 6 (5.1) | 1 (3.7) | 5 (5.5) | 0.71 | 1 (3.8) | 3 (5.8) | 0.717 |
| Cardiac tamponade | 17 (14.4) | 1 (3.7) | 16 (17.6) | 0.071 | 1 (3.8) | 5 (9.6) | 0.506 |
| Visceral ischaemia | 7 (5.9) | 0 (0) | 7 (7.7) | 0.137 | 0 (0) | 2 (3.8) | 0.666 |
| Limb ischaemia | 34 (28.8) | 4 (14.8) | 32 (35.2) | 0.047 | 3 (11.5) | 9 (17.3) | 0.506 |
| Previous cardiac surgery | 7 (5.9) | 1 (3.7) | 6 (6.6) | 0.577 | 0 (0) | 1 (1.9) | 0.83 |
| Extension of dissection | |||||||
| Asc Ao | 8 (6.8) | 1 (3.7) | 7 (7.7) | 0.469 | 1 (3.8) | 3 (5.8) | 0.827 |
| Asc Ao + Arch | 20 (16.9) | 4 (14.8) | 16 (17.6) | 0.736 | 4 (15.4) | 9 (17.3) | 0.815 |
| Asc Ao + Arch + Desc | 90 (76.3) | 22 (81.5) | 68 (74.7) | 0.468 | 21 (80.8) | 40 (76.9) | 0.361 |
Asc Ao: ascending aorta; BMI: body mass index; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease 2019; Desc: descending aorta; SD: standard deviation.
Operative variables
| Variables | Total ( | Non-matched cohort | Propensity matched cohort | ||||
|---|---|---|---|---|---|---|---|
| COVID-19 group January 2020–March 2020 ( | Control group January 2019–March 2019 ( |
| COVID-19 group January 2020–March 2020 ( | Control group January 2019–March 2019 ( |
| ||
| Waiting time to operation (h) mean ± SD | 13.7 ± 6.5 | 22.7 ± 8.3 | 8.1 ± 3.7 | <0.001 | 22.9 ± 8.3 | 9.7 ± 4.0 | <0.001 |
| Hybrid surgery | 21 (17.8) | 4 (14.8) | 27 (29.7) | 0.123 | 4 (15.4) | 9 (17.3) | 0.830 |
| Aortic root operation | 36 (30.5) | 6 (22.2) | 30 (33.0) | 0.287 | 6 (23.1) | 18 (34.6) | 0.135 |
| Operation time (min), mean ± SD | 437 ± 109 | 460 ± 116 | 429 ± 102 | 0.183 | 456 ± 116 | 414 ± 119 | 0.145 |
| Clamp time (min), mean ± SD | 118 ± 36 | 136 ± 35 | 112 ± 40 | 0.006 | 135 ± 36 | 103 ± 45 | 0.003 |
| CPB time (min), mean ± SD | 208 ± 57 | 228 ± 72 | 206 ± 44 | 0.055 | 226 ± 72 | 202 ± 52 | 0.098 |
| CA time (min), | 20 ± 9 | 24 ± 9 | 18 ± 9 | 0.003 | 24 ± 9 | 17 ± 8 | <0.001 |
| Transfusion of red blood cells (U), mean ± SD | 6.3 ± 2.8 | 6.8 ± 2.9 | 6.1 ± 2.9 | 0.27 | 6.8 ± 2.9 | 6.4±2.5 | 0.531 |
Including Bentall, David and Wheat operations.
Only for operations needing total arch replacement with deep hypothermia and circulatory arrest.
CA: circulatory arrest; COVID-19: coronavirus disease-2019; CPB: cardiopulmonary bypass; SD: standard deviation.
Early outcomes
| Variables | Total ( | Non-matched cohort | Propensity matched cohort | ||||
|---|---|---|---|---|---|---|---|
| COVID-19 group January 2020–March 2020 ( | Control group January 2019–March 2019 ( |
| COVID-19 group January 2020–March 2020 ( | Control group January 2019–March 2019 ( |
| ||
| 30-Day mortality (%) | 4 (3.4) | 1 (3.7) | 3 (3.3) | 0.908 | 1 (3.8) | 2 (3.8) | 1 |
| Stroke (%) | 6 (5.1) | 1 (3.7) | 5 (5.5) | 0.729 | 1 (3.8) | 3 (5.8) | 0.817 |
| Neurological deficit (%) | 6 (5.1) | 1 (3.7) | 5 (5.5) | 0.729 | 1 (3.8) | 4 (7.7) | 0.644 |
| Acute kidney injury (%) | 15 (12.7) | 2 (7.4) | 13 (14.3) | 0.166 | 2 (7.7) | 7 (13.5) | 0.488 |
| Pulmonary infection (%) | 29 (33.1) | 14 (51.9) | 25 (27.5) | 0.018 | 14 (53.8) | 10 (19.2) | 0.003 |
| ARDS (%) | 1 (0.8) | 0 (0) | 1 (1.1) | 0.584 | 0 (0) | 0 (0) | 1 |
| CPR (%) | 2 (1.7) | 0 (0) | 2 (2.2) | 0.437 | 0 (0) | 2 (3.8) | 0.311 |
| ECMO usage (%) | 0 (0) | 0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| Septic shock (%) | 0 (0) | 0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| Unplanned reintubation (%) | 5 (4.2) | 0 | 5 (5.5) | 0.248 | 0 (0) | 3 (5.8) | 0.212 |
| Reoperation (%) | 8 (6.8) | 1 (3.7) | 7 (7.7) | 0.419 | 1 (3.8) | 5 (9.6) | 0.367 |
| ICU time (days), mean ± SD | 5.2 ± 3.6 | 7.2 ± 3.9 | 4.3 ± 2.9 | <0.001 | 7.4 ± 3.8 | 4.5 ± 2.7 | 0.002 |
| Ventilation time (h), mean ± SD | 49 ± 23 | 79 ± 71 | 41 ± 20 | <0.001 | 81 ± 71 | 45 ± 19 | <0.001 |
| Postoperative qRT-PCR | N/A | 0 (0) | N/A | N/A | 0 (0) | N/A | N/A |
| COVID-19 IgM positive | N/A | 0 (0) | N/A | N/A | 0 (0) | N/A | N/A |
| COVID-19 IgG positive | N/A | 7 (25.9) | N/A | N/A | 7 (26.9) | N/A | N/A |
ARDS: acute respiratory syndrome; COVID-19: coronavirus disease-2019; CPR: cardiopulmonary resuscitation; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; IgM: Immunoglobulin M; IgG: Immunoglobulin G; qRT-PCR: quantitative real-time polymerase chain reaction.